Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
Ist Teil von
The New England journal of medicine, 2013-09, Vol.369 (11), p.999-1010
Ort / Verlag
Waltham, MA: Massachusetts Medical Society
Erscheinungsjahr
2013
Quelle
MEDLINE
Beschreibungen/Notizen
P2Y
12
inhibitors are effective in non–ST-segment elevation acute coronary syndromes, but the timing of drug dosing is unclear. In this trial, pretreatment with prasugrel, as compared with treatment after coronary angiography, did not improve outcomes and increased the risk of bleeding.
Clopidogrel does not become biologically and clinically effective until several hours after administration.
1
,
2
Although a loading dose of clopidogrel is required in patients undergoing percutaneous coronary intervention (PCI), it is uncertain whether pretreatment with clopidogrel (with treatment given early enough before catheterization to be effective) is efficient when the coronary-artery anatomy in a patient with a non–ST-segment elevation (NSTE) acute coronary syndrome is not known. Pretreatment can delay a coronary-artery bypass grafting (CABG) procedure or increase unnecessarily the risk of bleeding in patients who do not need to undergo PCI. Two randomized studies, one involving patients with NSTE acute . . .